Being able to offer innovative treatment options and thus improve the health and lives of our patients is the main power that drives us. Research and development area (R&D) is important to Chiesi not only as a technological focus company but for manufacturer of pharmaceuticals. The path from an idea to a custom treatment with an innovative medication is very long and often bumpy. This is why our R&D team has an interdisciplinary structure and forms a key part of our company.
The researchers and developers at various sites around the world are confronted on a daily basis with the challenges inherent in identifying new active substance candidates and developing modern medications. Our research and development strategy concentrate in part on preclinical and clinical research, quality assurance, and the development of technologies and pharmaceutical forms that enable better use of medications or allow their use to be easily monitored.
Our new Research and Development Centre is located in Parma, Italy. Along with the site in Parma, we have R&D divisions in Paris (France), Chippenham (Great Britain), Cary (US), Lidingo (Sweden), and Hillerod (Denmark).
Chiesi invests 15–20% of the total turnover of the Chiesi Group every year into research and development. This pays off: 75% of our turnover is generated by our own products.
Along with our core business in the therapeutic areas respiratory and neonatology, Chiesi also focuses on rare diseases, transplantation, gene therapy, and biotechnology.